Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes.
Συγγραφείς:	Sharpton S; Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Díaz LA; MASLD Research Center, University of California San Diego, La Jolla, California, USA.; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile., Pepin K; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.; Resoundant, Inc., Rochester, Minnesota, USA., Amangurbanova M; Icahn School of Medicine at Mount Sinai, NYC Health+Hospitals Queens, New York, New York, USA., Madamba E; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Bettencourt R; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Singh S; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Valasek M; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Dalupang M; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Tesfai K; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Middleton MS; Department of Radiology, University of California San Diego, La Jolla, California, USA., Behling C; Department of Pediatrics, University of California San Diego, La Jolla, California, USA., Dunn W; Division of Gastroenterology, University of Kansas Health System, Kansas City, Kansas, USA., Nakajima A; Department of Gastroenterology, Yokohama City University, Yokohama, Japan., Imajo K; Department of Gastroenterology, Yokohama City University, Yokohama, Japan., Ogawa Y; Department of Gastroenterology, Yokohama City University, Yokohama, Japan., Caussy C; Hospices Civils de Lyon, Département Endocrinologie, Diabète et Nutrition, Hôpital Lyon Sud, Pierre-Bénite, France., Halegoua-DeMarzio D; Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Mohanty A; Division of Gastroenterology, Boston University, Boston, Massachusetts, USA., Huang DQ; Division of Gastroenterology and Hepatology, National University of Singapore, Singapore, Singapore., Fuchs M; Central Virginia Veterans Affairs Healthcare System and Virginia Commonwealth University, Richmond, Virginia, USA., Hameed B; Division of Gastroenterology, University of California San Francisco, San Francisco, California, USA., Stine JG; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Balakrishnan M; Division of Gastroenterology, Baylor College of Medicine, Houston, Texas, USA., Gray M; Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, Birmingham, Alabama, USA., Rodriguez M; Florida Research Institute, Lakewood Ranch, Florida, USA., DeLeon A; Pinnacle Clinical Research, San Antonio, Texas, USA., Puskoor R; Pinnacle Clinical Research, Austin, Texas, USA., Vuppalanchi R; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Behari J; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Hansen L; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Miller C; Clinical Trials Manager, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Medici V; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA., Sarkar S; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of California Davis, Sacramento, California, USA., Boursier J; Centre Hospitalier Universitaire D'angers, HIFIH Laboratory, SFR ICAT 4208, Angers University France, Angers, France., Tincopa M; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Ajmera V; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Richards L; MASLD Research Center, University of California San Diego, La Jolla, California, USA., Sirlin CB; Department of Radiology, University of California San Diego, La Jolla, California, USA., Ehman RL; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA., Loomba R; MASLD Research Center, University of California San Diego, La Jolla, California, USA.; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.; Department of Epidemiology, University of California San Diego, La Jolla, California, USA.
Συλλογικό Έργο:	GOLDMINE consortium
Πηγή:	Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2026 Aug; Vol. 64 (3), pp. 334-344. Date of Electronic Publication: 2026 Apr 22.
Τύπος έκδοσης:	Journal Article; Multicenter Study
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE
Imprint Name(s):	Publication: Oxford : Wiley-Blackwell Original Publication: [Oxford, OX] : Blackwell Scientific Publications, [c1987-
Ιατρικοί όροι (MeSH):	Elasticity Imaging Techniques/methods , Magnetic Resonance Imaging/methods , Non-alcoholic Fatty Liver Disease*/diagnostic imaging, Liver Cirrhosis/diagnostic imaging ; Liver Cirrhosis/pathology ; Humans ; Prospective Studies ; Disease Progression ; Biomarkers ; Longitudinal Studies ; Female ; Male ; Adult ; Middle Aged
Περίληψη:	Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk stratification at scale, creating a need for validated non-invasive biomarkers, particularly imaging biomarkers, that can predict clinically meaningful disease progression and liver-related outcomes. Aims: To describe the design and rationale of the GOLDMINE study, established to determine whether non-invasive imaging biomarkers predict MASLD progression and liver-related clinical outcomes. Methods: GOLDMINE is an investigator-initiated, multi-centre, international longitudinal cohort enrolling up to 1000 adults with either biopsy-proven MASLD or MASLD cirrhosis across the full fibrosis spectrum. Participants are recruited from 15 sites in the US and 4 international sites (Japan, Singapore and France). At baseline, participants undergo clinical phenotyping, vibration-controlled transient elastography, and advanced magnetic resonance imaging (MRI), including proton-density-fat-fraction and magnetic resonance elastography (MRE). MRI (and biospecimen banking) is repeated at 2-year intervals (years 2 and 4), with annual follow-up visits for up to 10 years. Baseline liver histology is centrally processed, digitized and reviewed by a single expert hepatopathologist; all MRI/MREs are centrally interpreted. Results: The prespecified clinical outcomes include progression to cirrhosis, clinically significant portal hypertension, major adverse liver-related outcomes (ascites, hepatic encephalopathy, portal hypertensive bleeding, liver transplantation/qualification), hepatocellular carcinoma, major adverse cardiovascular events, and all-cause mortality, with independent central adjudication of all events. Conclusions: GOLDMINE establishes a rigorously phenotyped MASLD cohort integrating centralized histology, advanced MRI-based biomarkers, longitudinal biobanking, and adjudicated outcomes, providing a platform to validate imaging and blood-based prognostic biomarkers in MASLD. (© 2026 John Wiley & Sons Ltd.)
References:	Z. M. Younossi, P. Golabi, J. M. Paik, A. Henry, C. Van Dongen, and L. Henry, “The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review,” Hepatology 77, no. 4 (2023): 1335–1347. D. Q. Huang, V. W. S. Wong, M. E. Rinella, et al., “Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adults,” Nature Reviews. Disease Primers 11, no. 1 (2025): 14. L. A. Díaz, J. V. Lazarus, E. Fuentes‐López, et al., “Disparities in Steatosis Prevalence in the United States by Race or Ethnicity According to the 2023 Criteria,” Commun Med (Lond) 4, no. 1 (2024): 219. P. Ochoa‐Allemant, M. Serper, R. X. Wang, et al., “Waitlisting and Liver Transplantation for MetALD in the United States: An Analysis of the UNOS National Registry,” Hepatology 81, no. 2 (2025): 532–545. G. Targher, L. Valenti, and C. D. Byrne, “Metabolic Dysfunction‐Associated Steatotic Liver Disease,” New England Journal of Medicine 393, no. 7 (2025): 683–698. V. Ajmera, S. Cepin, K. Tesfai, et al., “A Prospective Study on the Prevalence of NAFLD, Advanced Fibrosis, Cirrhosis and Hepatocellular Carcinoma in People With Type 2 Diabetes,” Journal of Hepatology 78, no. 3 (2023): 471–478. H. Hagström, Y. Shang, H. Hegmar, and P. Nasr, “Natural History and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease,” Lancet Gastroenterology & Hepatology 9, no. 10 (2024): 944–956. N. Tamaki, N. Ahlholm, P. K. Luukkonen, et al., “Risk of Advanced Fibrosis in First‐Degree Relatives of Patients With Nonalcoholic Fatty Liver Disease,” Journal of Clinical Investigation 132, no. 21 (2022): e162513, https://doi.org/10.1172/JCI162513. P. S. Dulai, S. Singh, J. Patel, et al., “Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta‐Analysis,” Hepatology 65, no. 5 (2017): 1557–1565. A. J. Sanyal, M. L. Van Natta, J. Clark, et al., “Prospective Study of Outcomes in Adults With Nonalcoholic Fatty Liver Disease,” New England Journal of Medicine 385, no. 17 (2021): 1559–1569. D. Hudson, T. Afzaal, H. Bualbanat, et al., “Modernizing Metabolic Dysfunction‐Associated Steatotic Liver Disease Diagnostics: The Progressive Shift From Liver Biopsy to Noninvasive Techniques,” Therapeutic Advances in Gastroenterology 17 (2024): 17562848241276334. M. E. Rinella, B. A. Neuschwander‐Tetri, M. S. Siddiqui, et al., “AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease,” Hepatology 77, no. 5 (2023): 1797–1835. N. Thakral, H. Desalegn, L. A. Diaz, et al., “A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD,” Seminars in Liver Disease 44, no. 3 (2024): 273–286. N. Panagiotopoulos, T. Wolfson, D. T. Harris, et al., “Proton Density Fat Fraction for Diagnosis of Metabolic Dysfunction‐Associated Steatotic Liver Disease,” Hepatology 83, no. 1 (2026): 127–141. J. X. Liang, J. Ampuero, H. Niu, et al., “An Individual Patient Data Meta‐Analysis to Determine Cut‐Offs for and Confounders of NAFLD‐Fibrosis Staging With Magnetic Resonance Elastography,” Journal of Hepatology 79, no. 3 (2023): 592–604. N. Tamaki, N. Munaganuru, J. Jung, et al., “Clinical Utility of 30% Relative Decline in MRI‐PDFF in Predicting Fibrosis Regression in Non‐Alcoholic Fatty Liver Disease,” Gut 71, no. 5 (2022): 983–990. B. Koh, J. Xiao, C. H. Ng, et al., “Comparative Efficacy of Pharmacologic Therapies for MASH in Reducing Liver Fat Content: Systematic Review and Network Meta‐Analysis,” Hepatology 83, no. 1 (2026): 117–126. R. Loomba, M. Amangurbanova, R. Bettencourt, et al., “MASH Resolution Index: Development and Validation of a Non‐Invasive Score to Detect Histological Resolution of MASH,” Gut 73, no. 8 (2024): 1343–1349. R. Loomba, P. C. Y. N. Daniel, M. Amangurbanova, et al., “Head‐To‐Head Comparison of MASH Resolution Index Versus FAST for Noninvasive Prediction of Resolution of MASH on Biopsy,” Hepatology 83 (2025): 907–914, https://doi.org/10.1097/HEP.0000000000001396. S. Singh, L. L. Fujii, M. H. Murad, et al., “Liver Stiffness Is Associated With Risk of Decompensation, Liver Cancer, and Death in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐Analysis,” Clinical Gastroenterology and Hepatology 11, no. 12 (2013): 1573–1584.e1–2; quiz e88–9. C. Hsu, C. Caussy, K. Imajo, et al., “Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants,” Clinical Gastroenterology and Hepatology 17, no. 4 (2019): 630–637.e8. R. K. Sterling, A. Duarte‐Rojo, K. Patel, et al., “AASLD Practice Guideline on Imaging‐Based Noninvasive Liver Disease Assessment of Hepatic Fibrosis and Steatosis,” Hepatology 81, no. 2 (2025): 672–724. J. Chen, M. Yin, J. A. Talwalkar, et al., “Diagnostic Performance of MR Elastography and Vibration‐Controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients With Severe to Morbid Obesity,” Radiology 283, no. 2 (2017): 418–428. Y. j. Lee, J. M. Lee, J. E. Lee, et al., “MR Elastography for Noninvasive Assessment of Hepatic Fibrosis: Reproducibility of the Examination and Reproducibility and Repeatability of the Liver Stiffness Value Measurement,” Journal of Magnetic Resonance Imaging 39, no. 2 (2014): 326–331. GBD 2021 US Obesity Forecasting Collaborators, “National‐Level and State‐Level Prevalence of Overweight and Obesity Among Children, Adolescents, and Adults in the USA, 1990–2021, and Forecasts Up to 2050,” Lancet 404 (2024): 2278–2298, https://doi.org/10.1016/S0140‐6736(24)01548‐4. J. A. Gwira, C. D. Fryar, and Q. Gu, “Prevalence of Total, Diagnosed, and Undiagnosed Diabetes in Adults: United States, August 2021‐August 2023,” NCHS Data Brief no. 516 (2024): CS354814, https://doi.org/10.15620/cdc/165794. S. I. Asahara, H. Miura, W. Ogawa, and Y. Tamori, “Sex Difference in the Association of Obesity With Personal or Social Background Among Urban Residents in Japan,” PLoS One 15, no. 11 (2020): e0242105. N. Ikeda, N. Nishi, H. Noda, and M. Noda, “Trends in Prevalence and Management of Diabetes and Related Vascular Risks in Japanese Adults: Japan National Health and Nutrition Surveys 2003‐2012,” Diabetes Research and Clinical Practice 127 (2017): 115–122. US Census Bureau, “Census.gov,” cited December 19, 2025, U.S. Census Bureau Homepage, https://www.census.gov/. L. A. Díaz, W. Alazawi, S. Agrawal, et al., “High Inherited Risk Predicts Age‐Associated Increases in Fibrosis in Patients With MASLD,” Journal of Hepatology 83 (2025): 849–859, https://doi.org/10.1016/j.jhep.2025.04.035.
Grant Information:	AstraZeneca
Contributed Indexing:	Keywords: NAFLD; fatty liver; metabolic dysfunction‐associated steatotic liver disease; non‐alcoholic fatty liver disease; non‐alcoholic steatohepatitis
Substance Nomenclature:	0 (Biomarkers)
Entry Date(s):	Date Created: 20260422 Date Completed: 20260712 Latest Revision: 20260726
Update Code:	20260726
PubMed Central ID:	PMC13356296
DOI:	10.1111/apt.70696
PMID:	42017265
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1365-2036
DOI:	10.1111/apt.70696